<SEC-DOCUMENT>0001104659-24-115049.txt : 20241107
<SEC-HEADER>0001104659-24-115049.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107070512
ACCESSION NUMBER:		0001104659-24-115049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TREVENA INC
		CENTRAL INDEX KEY:			0001429560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36193
		FILM NUMBER:		241433092

	BUSINESS ADDRESS:	
		STREET 1:		955 CHESTERBROOK BOULEVARD
		STREET 2:		SUITE 110
		CITY:			CHESTERBROOK
		STATE:			PA
		ZIP:			19087
		BUSINESS PHONE:		6103548840

	MAIL ADDRESS:	
		STREET 1:		955 CHESTERBROOK BOULEVARD
		STREET 2:		SUITE 110
		CITY:			CHESTERBROOK
		STATE:			PA
		ZIP:			19087
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2427743d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:trvn="http://trevenainc.com/20241105">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_trvn_trevenainc.com_20241105 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20241105_20241105 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001429560 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000004" name="dei:EntityCentralIndexKey">0001429560</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="trvn-20241105.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001429560</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-05</xbrli:startDate>
        <xbrli:endDate>2024-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20241105__20241105_z9UnV0NcbLX7"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_908_edei--DocumentPeriodEndDate_c20241105__20241105_z07pXFThLkpj"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 5, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20241105__20241105_zjRtgNTACO41"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000011" name="dei:EntityRegistrantName">TREVENA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20241105__20241105_z6y41xA3cYFi"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityFileNumber_c20241105__20241105_zGVkmmV0U6y4"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000013" name="dei:EntityFileNumber">001-36193</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; width: 2%; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 49%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20241105__20241105_zHZysKcMddB2"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1469215</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br/>

    File No.)</span></td>
    <td style="text-align: center; vertical-align: bottom">&#160; &#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/> Identification No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20241105__20241105_zRINyW4dlOo9"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000015" name="dei:EntityAddressAddressLine1">955 Chesterbrook Boulevard</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20241105__20241105_zXQ1sdsV7duh"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 110</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20241105__20241105_zrx1NPtY7UZ7"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000017" name="dei:EntityAddressCityOrTown">Chesterbrook</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20241105__20241105_zCRSLUnYFDmh"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000018" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20241105__20241105_zo5rajJF6Y5k"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000019" name="dei:EntityAddressPostalZipCode">19087</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_905_edei--CityAreaCode_c20241105__20241105_zDMxWq2a6csl"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000020" name="dei:CityAreaCode">610</ix:nonNumeric></span></b><b>) <span id="xdx_90B_edei--LocalPhoneNumber_c20241105__20241105_z5CTAXae0NQe"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000021" name="dei:LocalPhoneNumber">354-8840</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20241105__20241105_zlWsZsBvGWn8"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20241105__20241105_zBQLL6ry2Ub7"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20241105__20241105_zpwEPgUDa3H2"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20241105__20241105_zoC0sDjkoAGa"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Title of each class</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Trading Symbol(s)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Name of each exchange on which<br/>
 &#8239;registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_edei--Security12bTitle_c20241105__20241105_zi6EAazb3ya4"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_edei--TradingSymbol_c20241105__20241105_z2lBPWBwdin4"><ix:nonNumeric contextRef="AsOf2024-11-05" id="Fact000027" name="dei:TradingSymbol">TRVN</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">OTC Pink Open Market
</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging
growth company </span><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20241105__20241105_zNOF5zG0Nzj1" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-11-05" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 2.02</b></td><td><b>Results of Operations and Financial Condition.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 7, 2024, Trevena, Inc. (the &#8220;Company&#8221;) issued
a press release announcing its financial results for the quarter ended September 30, 2024, and provided an overview of its third quarter
operational updates. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information under this caption and contained in the press release
attached hereto as Exhibit 99.1 is furnished by the Company in accordance with Securities Exchange Commission Release No. 33-8216. This
information shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such
a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 5.02</b></td><td><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Departures of Certain Directors </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 5, 2024, in connection with ongoing cost-cutting measures,
each of Mark Corrigan, M.D., Marvin Johnson, Jr., Anne M. Phillips, M.D., and Jake R. Nunn resigned from the Board of Directors of the
Company (the &#8220;Board&#8221;) and the committees thereof, effective as of November 5, 2024. The voluntary resignations of such directors
were not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the foregoing resignations, the Board decreased
the size of the Board to three members, effective upon the effectiveness of the resignations. Following the effectiveness of the resignations,
Carrie Bourdow continues to serve as Chairman of the Board, and Scott Braunstein, M.D. and Barbara Yanni continue to serve as directors
on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Consulting Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 6, 2024, the Company entered into a consulting agreement
with Ms. Bourdow (the &#8220;Bourdow Consulting Agreement&#8221;), effective as of November 6, 2024, pursuant to which Ms. Bourdow will
continue to provide services to the Company in her capacity as Acting Chief Executive Officer and Principal Executive Officer of the Company.
Pursuant to the terms of the Bourdow Consulting Agreement, Ms. Bourdow will receive cash compensation at an hourly rate generally consistent
with her prior compensation levels for services to the Company. A copy of the Bourdow Consulting Agreement is filed as Exhibit 10.1 to
this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01.</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">(d)</td><td style="text-align: justify"><span style="text-decoration: underline">Exhibits</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 8%; padding: 0.25pt 0.25pt 0.5pt"><b>Number</b></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 90%; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2427743d1_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2427743d1_ex99-1.htm" style="-sec-extract: exhibit">Press Release dated November 7, 2024</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2427743d1_ex10-1.htm">10.1</a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2427743d1_ex10-1.htm">Consulting Agreement, dated November 6, 2024, by and between the Company and Carrie Bourdow</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">104</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">SIGNATURES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%"><b>TREVENA, INC.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Date: November 7, 2024 </td>
    <td>By:</td>
    <td style="border-bottom: black 1pt solid">/s/ Barry Shin</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Barry Shin</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Acting Chief Operating Officer and Chief Financial Officer</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Oky3hPIyKYksQiK6XXKMJd2R2e3vkXrLNiUaBobhnO8cIUYip5VukOG0KAs4YNs1yiGUWCOjOaN3ZOtNCv6WeNHWsTKuf39gRp5BzyShnCgv9Na7tlilEM3Gcj6WU4jiNElgvxXBV8/I1LpC47RqQJkK9kwda3SKX0PCQT3JUPvqq47IVpNJIQ6jQX6DjGIJO7qrB/HVQlFkIhj1E4ic6dZ51/Lp0HxJWDbY+jo70P8NPg0JSpc= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2427743d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CONSULTING AGREEMENT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EFFECTIVE
DATE: November&nbsp;6, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>This
Consulting Agreement </B></FONT>(the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made by and between <FONT STYLE="font-variant: small-caps"><B>Trevena,&nbsp;Inc.
</B></FONT>a Delaware corporation (&ldquo;<B><I>Client</I></B>&rdquo;), and Carrie Bourdow (the &ldquo;<B><I>Consultant</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Engagement
of Services. </B>Subject to the terms of this Agreement, Consultant will render the services set forth in the Project Proposal attached
hereto as Exhibit&nbsp;A (the <B><I>&ldquo;Services&rdquo;</I></B>) by the completion dates and within the budgets set forth therein.
Consultant acknowledges that any and all payments received shall be fair value payments for services provided and not intended to be,
or deemed to be a bribe, kickback or any other form of payment which would violate applicable laws. No payments made by Client to Consultant
are intended to influence current or future prescribing decisions or otherwise influence Consultant&rsquo;s opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Compensation.
</B>Client will pay Consultant fees and expenses as set forth in each Project Proposal for services rendered pursuant to this Agreement.
Any fees or expenses which will exceed amounts proposed in the Project Proposal must be pre-approved by Client before such fees or expenses
are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Ownership
of Work Product. </B>Consultant hereby irrevocably assigns, grants and conveys to Client all right, title and interest now existing or
that may exist in the future in and to any work performed by Consultant for Client, including without limitation any ideas, designs, techniques,
inventions, know-how, software, copyrights, trademarks, patents and any other intellectual property or other rights in any work product
created by Consultant, or to which Consultant contributes or relies upon or incorporates any Client Confidential Information, pursuant
to this Agreement (the &ldquo;<B><I>Work Product</I></B>&rdquo;). Consultant agrees that any and all Work Product shall be and remain
the property of Client. Consultant agrees to execute, at Client&rsquo;s request and expense, all documents and other instruments necessary
or desirable to confirm Client&rsquo;s rights and transfer to Client such rights in all Work Product. In the event that Consultant does
not, for any reason, execute such documents within a reasonable time of Client&rsquo;s request, Consultant hereby irrevocably appoints
Client as Consultant&rsquo;s attorney-in-fact for the purpose of executing any and all documents on Consultant&rsquo;s behalf necessary
to facilitate the transfer and assignment to Client of all rights to the Work Product. The appointment of Client as Consultant&rsquo;s
attorney-in-fact is coupled with an interest. Consultant shall not attempt to register any works or Work Product created by Consultant
pursuant to this Agreement at the U.S. Copyright Office, the U.S. Patent&nbsp;&amp; Trademark Office, or any foreign copyright, patent,
or trademark registry. Consultant retains no rights in the Work Product and agrees not to challenge Client&rsquo;s ownership of the rights
embodied in the Work Product. Consultant shall take all necessary actions to assist Client to enforce Client&rsquo;s rights relating to
the Work Product in any and all countries, including, but not limited to, executing, verifying and delivering such documents and performing
such other acts (including appearing as a witness) as Client may reasonably request for use in obtaining, perfecting, evidencing, sustaining
and enforcing Client&rsquo;s rights relating to the Work Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Artist&rsquo;s,
Moral, and Other Rights. </B>If Consultant has any rights, including without limitation &ldquo;artist&rsquo;s rights&rdquo; or &ldquo;moral
rights,&rdquo; in the Work Product which cannot be assigned (the &ldquo;<B><I>Non-Assignable Rights</I></B>&rdquo;), Consultant agrees
to waive enforcement worldwide of such rights against Client. In the event that Consultant has any such rights that cannot be assigned
or waived, Consultant hereby grants to Client a royalty-free, paid-up, exclusive, worldwide, irrevocable, perpetual license to the Non-Assignable
Rights to (i)&nbsp;use, make, have made, sell, offer to sell, import, and further sublicense the Work Product, and (ii)&nbsp;reproduce,
distribute, create derivative works of, publicly perform and publicly display the Work Product, including any Non- Assignable Rights,
in any medium or format, whether now known or later developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Warranties. </B>Consultant represents and warrants that: (a)&nbsp;Consultant has the full right and authority to enter into this
Agreement and perform his obligations hereunder, (b)&nbsp;Consultant has the right and unrestricted ability to produce and, if necessary,
assign the Work Product to Client as set forth in Section&nbsp;3 (including without limitation the right to assign any Work Product created
by Consultant&rsquo;s employees or contractors as and when created or produced), (c)&nbsp;the Work Product has not and will not be based
upon and does not incorporate any third party proprietary information, (d)&nbsp;the Work Product will not infringe upon any copyright,
patent, trademark, right of publicity or privacy, or any other proprietary right of any person, whether contractual, statutory or common
law, (e)&nbsp;he is duly licensed, to the extent required, in the state(s), province(s)&nbsp;and/or country in which he is currently
practicing and (f)&nbsp;he has not been excluded, debarred, suspended, or otherwise ineligible to participate in federal and/or state
programs, or named on the List of Excluded Individuals/Entities issued by the Office of Inspector General of the U.S. Department of Health
and Human Services Office and/or the Debarment List of the U.S. Food and Drug Administration. Consultant agrees to indemnify Client from
any and all damages, costs, claims, expenses or other liability (including reasonable attorneys&rsquo; fees and expenses) arising from
or relating to the breach or alleged breach by Consultant of the representations and warranties set forth in this Section&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Independent
Contractor Relationship. </B>Consultant is an independent contractor, and nothing in this Agreement is intended to, or should be construed
to, create a partnership, agency, joint venture or employment relationship. Consultant will not be entitled to any of the benefits which
Client may make available to its employees, including, but not limited to, group health or life insurance, profit-sharing or retirement
benefits. The manner and means by which Consultant chooses to complete the Projects are in Consultant&rsquo;s sole discretion and control. In
completing the Projects, Consultant agrees to provide its own equipment, tools and other materials at its own expense. Unless otherwise
approved by Client, Consultant is not and shall not be considered the agent of Client and is not authorized to make any representation,
contract, or commitment on behalf of Client. Consultant is solely responsible for, and will timely file all tax returns and payments required
to be filed with, or made to, any federal, state or local tax authority with respect to the performance of services and receipt of fees
under this Agreement. Consultant is solely responsible for, and must maintain adequate records of, expenses incurred in the course of
performing services under this Agreement. No part of Consultant&rsquo;s compensation will be subject to withholding by Client for the
payment of any social security, federal, state or any other employee payroll taxes. Client will regularly report amounts paid to Consultant
by filing Form&nbsp;1099-MISC with the Internal Revenue Service as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Confidential
Information. </B>Consultant agrees to hold Client&rsquo;s Confidential Information in strict confidence and not to disclose such Confidential
Information to any third parties except to employees that require the information in order to perform the Services under this Agreement
and who are under written agreement or otherwise bound by obligations of confidentiality to Consultant. Consultant also agrees not to
use any of Client&rsquo;s Confidential Information for any purpose other than performance of the Services. &ldquo;Confidential Information&rdquo;
as used in this Agreement shall mean all information disclosed by Client to Consultant, or otherwise obtained by Consultant pursuant to
Services provided under this Agreement, whether or not such information has been identified as confidential or that by the nature of the
information or the circumstances surrounding disclosure ought reasonably to be treated as confidential and/or proprietary, including,
but not limited to, any oral, written, graphic or machine-readable information including, without limitation, (a)&nbsp;concepts and ideas
relating to the development, distribution, engineering, manufacturing, marketing, servicing or financing of the current, future and proposed
products or services of Client or its subsidiaries or affiliates; (b)&nbsp;trade secrets, patent applications, drawings, claims, know
how, information, data, results, prices, techniques, inventions, ideas, processes and formulae; (c)&nbsp;samples, compounds, extracts,
media, vectors and/or cell lines and procedures and formulations for producing any such samples, compounds, extracts, media, vectors and/or
cell lines; (d)&nbsp;information regarding current and future plans for research, development, protocols, new service offerings or products,
marketing and selling, business plans, business forecasts, budgets and unpublished financial statements, licenses and distribution arrangements,
prices and costs, suppliers and customers; and (e)&nbsp;any information regarding the skills and compensation of employees, contractors
or other agents of the Client or its subsidiaries or affiliates. Confidential Information also includes proprietary or confidential information
of any third party who may disclose such information to Client or Consultant in the course of Client&rsquo;s business. Consultant&rsquo;s
obligations set forth in this Section&nbsp;7 shall not apply with respect to any portion of the Confidential Information that Consultant
can document by competent proof that such portion: (i)&nbsp;is in the public domain through no fault of Consultant; (ii)&nbsp;has been
rightfully independently communicated to Consultant free of any obligation of confidence; or (iii)&nbsp;was developed by Consultant independently
of and without reference to any information communicated to Consultant by Client. In addition, Consultant may disclose Client&rsquo;s
Confidential Information to the limited extent required by a valid order of a court or other governmental body, or as otherwise required
by law, provided that Consultant provides prompt written notice of such order so as to afford Client a sufficient amount of time to seek
protection for its Confidential Information. All Confidential Information furnished to Consultant by Client is the sole and exclusive
property of Client or its suppliers or customers. Upon request by Client, Consultant agrees to promptly deliver to Client the original
and any copies of such Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Securities
Acknowledgment. </B>Consultant acknowledges that (i)&nbsp;it is a violation of the federal securities laws to buy or sell securities of
a company while in possession of material, non-public information, (ii)&nbsp;it is illegal for a person in possession of material, non-public
information to provide other people with the material, non-public information or recommend that they buy or sell the securities and (iii)&nbsp;compliance
with the federal securities laws is solely the Consultant&rsquo;s responsibility. While in possession of material, nonpublic information,
each of Consultant and any of Consultant&rsquo;s employees, vendors and/or contractors providing Services hereunder shall refrain from
buying or selling Client&rsquo;s securities until this material, non-public information is made public by Client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Consultant&rsquo;s
Indemnification and Insurance</B>. (a)&nbsp;Consultant shall save, defend, indemnify and hold Client, its Affiliates and their respective
officers, directors, employees and agents harmless from and against any and all losses, damages, liabilities, costs and expenses (including
reasonable attorney&rsquo;s fees and expenses) arising in connection with any and all charges, complaints, actions, suits, proceedings,
hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a third party, resulting or otherwise
arising from or in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Consultant&rsquo;s
willful breach of its obligations, covenants, representations or warranties contained in this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>any
willful misconduct of Consultant or any other parties involved in the fulfillment of Consultant&rsquo;s obligations and the Services under
this Agreement, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
willful infringement, violation or misappropriation by Consultant of another party&rsquo;s intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">(b)&nbsp;Client shall save, defend, indemnify and hold Consultant,
its Affiliates and their respective officers, directors, employees and agents harmless from and against any and all losses, damages, liabilities,
costs and expenses (including reasonable attorney&rsquo;s fees and expenses) arising in connection with any and all charges, complaints,
actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a third
party, resulting or otherwise arising from Consultant&rsquo;s Services under this Agreement, except only to the extent that such action
by a third party arose from Consultant&rsquo;s wilful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Conflict of Interest. </B>During the term of this Agreement, Consultant will not accept work, enter into a contract, or accept an obligation
from any third party, inconsistent, in conflict with or incompatible with Consultant&rsquo;s obligations, or the scope of services rendered
for Client, under this Agreement. Consultant warrants that there is no other contract or duty on its part inconsistent with or conflict
with this Agreement. Consultant shall not accept an obligation from a third party which is inconsistent, in conflict with or incompatible
with Consultant&rsquo;s obligations, or the scope of Services rendered for Client, under this Agreement. Consultant shall indemnify Client
from any and all losses, claims, causes of action or liabilities it may incur if Consultant violates this Section&nbsp;10 or any other
provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD><B>Term and Termination.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Term.
</B>This Agreement shall be effective on the Effective Date and shall remain in effect until terminated by either party as provided in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Termination.
</B>Either party may terminate this Agreement at any time upon fifteen (15) days prior written notice to the other for any reason or no
reason. Client may also terminate this Agreement immediately in its sole discretion upon Consultant&rsquo;s material breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Survival.
</B>The rights and obligations contained in Sections 3 (&ldquo;<B><I>Ownership of Work Product</I></B>&rdquo;), 4 (&ldquo;<B><I>Artist&rsquo;s,
Moral, and Other Rights</I></B>&rdquo;), 5 (&ldquo;<B><I>Representations and Warranties</I></B>&rdquo;), 7 (&ldquo;<B><I>Confidential
Information</I></B>&rdquo;), and 8 (&ldquo;<B><I>Securities Acknowledgement</I></B>&rdquo;) shall survive any termination or expiration
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Successors
and Assigns. </B>Consultant may not subcontract or otherwise delegate its obligations under this Agreement without Client&rsquo;s prior
written consent. Client may assign this Agreement. Subject to the foregoing, this Agreement will be for the benefit of Client&rsquo;s
successors and assigns, and will be binding on Consultant&rsquo;s subcontractors or delegatees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notices.
</B>Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given
as indicated: (i)&nbsp;by overnight courier upon written verification of receipt; or (ii)&nbsp;by telecopy or facsimile transmission upon
acknowledgment of receipt of electronic transmission. Notice shall be sent to the addresses set forth below or such other address as either
party may specify in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Governing
Law. </B>This Agreement shall be governed in all respects by the laws of the State of Delaware, as such laws are applied to agreements
entered into and to be performed entirely within the State of Delaware between Delaware residents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Severability.
</B>Should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the legality, validity
and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Waiver.
</B>The waiver by Client of a breach of any provision of this Agreement by Consultant shall not operate or be construed as a waiver of
any other or subsequent breach by Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Injunctive
Relief for Breach. </B>Consultant&rsquo;s obligations under this Agreement are of a unique character that gives them particular value;
breach of any of such obligations may result in irreparable and continuing damage to Client for which there will be no adequate remedy
at law; and, in the event of such breach, Client will be entitled to seek injunctive relief and/or a decree for specific performance,
and such other and further relief as may be proper (including monetary damages if appropriate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Entire
Agreement. </B>This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all
prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all services
undertaken by Consultant for Client. Notwithstanding the forgoing, the terms and provisions of that certain Indemnification Agreement
by and between the parties hereto, dated as of May&nbsp;4, 2015, shall remain in full force and effect. This Agreement may only be changed
by mutual agreement of authorized representatives of the parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>This
Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original copy of the Agreement, and
all of which, when taken together, shall be deemed to constitute one and the same Agreement. The Parties consent to use DocuSign,
CLIENT&rsquo;S ISO/IEC 27001 certified e-signature service for purposes of electronically signing this Agreement, which e-signatures
shall be given the same legal force and effect as the physical delivery of this Agreement bearing an original manual signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[</B></FONT><B><FONT STYLE="font-size: 10pt">SIGNATURE
PAGE FOLLOWS</FONT>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">Trevena Consulting Agreement</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->.</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>In
Witness Whereof, </B></FONT>the parties have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;Client&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Trevena,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Robert Yoder</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Printed Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Robert Yoder</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Business Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">955 Chesterbrook Boulevard, Suite&nbsp;110</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chesterbrook, PA 19087</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;CONSULTANT&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARRIE L. BOURDOW</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Carrie L. Bourdow</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Printed Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Carrie L. Bourdow</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3276 Barley Lane</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Lansdale, PA 19446</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>Exhibit&nbsp;A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>PROJECT PROPOSAL/SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>Project:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Consultant will provide assistance, advice and expertise
on pipeline assets, corporate strategy and other business topics as directed by the client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>Fees and Reimbursement:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Fees: $550/hr.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.</B></FONT><B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Reimbursement
for the following pass-through costs, as pre-approved in advance by Client and incurred as part of performing the Services described herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD>Travel fee (any travel time shall be invoiced at &frac12; Consultant&rsquo;s hourly fee).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD>Reasonable and necessary travel fees and arrangements in accordance with Trevena&rsquo;s Travel&nbsp;&amp; Expense Policy which is
attached to, and incorporated into, this Exhibit&nbsp;A as Schedule I (the &ldquo;T&amp;E Policy&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD>Other reasonable and necessary direct costs incurred as part of the performance of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD>Reasonable meals and lodging associated with any travel required while performing the Services in accordance with the T&amp;E Policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Consultant
shall invoice Client monthly for services and expenses and shall provide such reasonable receipts or other documentation of fees and
expenses as Client might request, including copies of detailed time records. All invoices shall be submitted in &ldquo;portable document
format&rdquo; (&ldquo;.pdf&rdquo;) to <I><U>accountspayable@Trevena.com</U></I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Payment terms: net thirty (30) days from Client&rsquo;s receipt
of invoice. Client will be invoiced on the first day of each month for services rendered and expenses incurred during the previous month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C.</B></FONT></TD><TD>In the event this Project Proposal or the parties&rsquo; underlying consulting agreement is terminated prior to the completion of
this Project, Client shall pay Consultant for all fees earned through the effective date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>SCHEDULE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T&amp;E POLICY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" COLSPAN="2" STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2427743d1_ex10-1img01.jpg" ALT=""></FONT></P></TD>
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Document Identifier</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FIN-POL-0001-US-GDL-02</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Effective Date</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">December&nbsp;15, 2020</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Revision Number</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2.0</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Location</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">US</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt; border-left: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEPARTMENT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; border-bottom: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">uidance on Travel and Expenses for Service Providers</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 15%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Travel
and Expense Guidelines for Consultants, Contractors, Vendors, etc. (&ldquo;Service Providers&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reasonable out-of-pocket applicable expenses incurred in accordance
with  Trevena&rsquo;s Travel and Expense Policy will be reimbursed at
cost to Service Providers provided that such expenses are deemed appropriate business expenses and the expenses are properly reported
and accompanied by appropriate supporting documentation. Out-of-pocket expenses are those incremental expenses the Service Providers incur
in the delivery of the services provided. For example, ongoing home office expenses, would not be considered out-of-pocket and are not
reimbursable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any Service Provider requesting reimbursement for any such reimbursable
expense is required to complete a standard expense reimbursement form and submit the completed form, along with all supporting documentation,
to the Company&rsquo;s designated supervisor. Appropriate supporting documentation includes the original receipt, invoice, or other similar
evidence of payment. Credit card statements are not generally considered acceptable supporting documentation and should only be used in
the absence of a receipt on an exception basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All Service Providers are expected to use good business judgement when
incurring reimbursable expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Expenses incurred shall conform to Trevena&rsquo;s standard expense guidelines below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 17.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Airline Travel </B> &ndash; actual costs of the airfare shall be
                                                                                                                               charged. Coach class is required to be booked for all flights within the United States. Any exceptions must be approved in advance
                                                                                                                               by Trevena senior management or their designee. International flights must also gain prior approval from the company designee.
                                                                                                                               Trevena will not pay for any first-class travel or for travel or expenses for individuals other than the Service Provider (such as
                                                                                                                               spouses, partners, or family members). No hourly labor rate shall apply during travel times unless Consultant&rsquo;s written
                                                                                                                               agreement with Trevena specifically allows such compensation. Service Providers shall schedule airline travel fourteen (14) days in
                                                                                                                               advance, unless otherwise agreed to in writing by Trevena. The cost of reasonable ground transportation, parking,</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">etc.
                                                                                                                               for business travel shall be charged at actual cost incurred, including any reasonable gratuities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 17.85pt">b)</TD><TD><B>Ground Transportation &ndash;</B> in the event Service
                                                               Providers utilizes his/her own vehicle to travel to the venue of a scheduled event, the current IRS mileage standard per mile shall
                                                               be charged plus any tolls and/or parking costs incurred. If the Parties agree to the use of a rental car, actual costs plus fuel and
                                                               tolls will be reimbursed. Single travelers renting a car must rent &ldquo;intermediate-size&rdquo; automobile or smaller. When
                                                               traveling in a group, renting a vehicle
appropriate to the group size is reimbursable. Rail transportation may be a more convenient means of travel than airline or automobile.
Fares are reimbursed at coach class rail rates unless previously approved by Trevena&rsquo;s senior management or their designee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.95pt"></TD><TD STYLE="width: 18pt">c)</TD><TD><B>Taxi/Car Services &ndash;</B> Taxi or car services, such
as Uber or Lyft used in connection with travel for Services will be reimbursed in full. &rsquo;&lsquo;Black Car&rsquo;&rsquo; or &rsquo;&lsquo;limousine&rsquo;&rsquo; services (including
such services as Uber Black and Lyft Lux) are not reimbursable unless approved in advance by the Company&rsquo;s CEO or her/his designees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 17.85pt">d)</TD><TD><B>Lodging &ndash; </B> standard, single room rates shall be
charges using reasonably priced facilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 17.9pt">e)</TD><TD><B>Meals &ndash; </B> Reasonable costs of business meals in
connection with the provision of Services will be reimbursed in full. In all cases, the people who attended the meal and the business
purpose should be written on the receipt. The cost of meals for a service provider not traveling for Services are generally not reimbursable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">1
of 3</FONT></B></TD>
  <TD STYLE="width: 90%">This material is the property of Trevena and must not be disclosed
except as authorized in writing. This document is controlled electronically. If you are accessing it by means other than the Trevena
SharePoint Site, then you may not have the latest version and the information and integrity cannot be guaranteed.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" COLSPAN="2" STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2427743d1_ex10-1img01.jpg" ALT=""></FONT></P></TD>
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Document Identifier</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FIN-POL-0001-US-GDL-02</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Effective Date</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">December&nbsp;15, 2020</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Revision Number</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2.0</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Location</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">US</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt; border-left: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEPARTMENT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; border-bottom: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">uidance on Travel and Expenses for Service Providers</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 15%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Reimbursement will be on the basis of actual costs including
taxes and reasonable tips (15-20%). To comply with tax regulations, the following information must be included on the expense report
for all business meals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name,
title, and company of all attendees</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
and location of establishment where event took place</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount
and date of expense</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Specific
business topic(s)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Detailed
credit card slip outlining charges must be attached</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Guidelines
for total or per-meal expenses are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Breakfast:
<B>$15.00 </B>dollars</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Lunch: <B>$20.00 </B>dollars</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Dinner: <B>$50.00 </B>dollars; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Total per Day: $<B>85.00 </B>dollars</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.95pt"></TD><TD STYLE="width: 18pt">f)</TD><TD><B>Incidentals </B> &ndash; incidentals such as personal items,
in-room movies and other forms of entertainment are not reimbursable by Trevena, as well as personal expenses, without exception, such
as health club or spa, clothing, souvenirs, gifts, flowers, dependent care, optional travel/life insurance and pet care.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Expense Reporting and Documentation Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Original
receipts are required for all expenses over $25.00 USD, or equivalent, and must indicate vendor name, location, date of expense,
description of item(s)</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">or service(s), and proof of payment
(i.e. check, credit card imprint, paid cash receipt). The original receipt completed by the vendor must be attached to the expense
report when submitted. </FONT>Receipts must be made out to the employee, not the Company. If a receipt is not available, a copy of
the credit card statement and a full explanation of the expense and reason for the missing original receipt are required.
Photocopies of receipts will be accepted only with a detailed explanation as to why the original is unavailable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
IRS code requires reimbursable expenditures to be supported by adequate records which clearly establish that they were (i)</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary
and necessary, (ii)</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">reasonable in amount and (iii)</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">incurred
for a valid business purpose. As such, please provide the following information on your expense report:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">the identity of the vendor or supplier must be indicated;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">the business purpose for the expenditure must be stated; and,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">c)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
identity and business relationship of others participating in the event (e.g., entertainment, business meal,</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">etc.)
covered by the expenditure must be stated</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Original itemized receipts (e.g., itemized hotel bills,
airline passenger receipt coupons, automobile rental invoices, taxi fares, parking receipts, telephone bills) must be submitted in an
organized manner maintaining a chronological order. No receipts are required for mileage allowances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">2
  of 3</FONT></B></TD>
  <TD STYLE="width: 90%">This material is the property of Trevena and must not be disclosed
except as authorized in writing. This document is controlled electronically. If you are accessing it by means other than the Trevena
SharePoint Site, then you may not have the latest version and the information and integrity cannot be guaranteed.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" COLSPAN="2" STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.95pt"><IMG SRC="tm2427743d1_ex10-1img01.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Document Identifier</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FIN-POL-0001-US-GDL-02</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Effective Date</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">December&nbsp;15, 2020</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-bottom: 6pt; border-left: Black 2.5pt double">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Revision Number</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2.0</P></TD>
    <TD STYLE="border-right: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; text-align: center; padding-bottom: 6pt">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Location</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">US</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt; border-left: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEPARTMENT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 2.5pt double; border-top: Black 2.5pt double; border-left: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBJECT:</B></FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 2.5pt double; border-right: Black 2.5pt double; border-bottom: Black 2.5pt double; padding-top: 6pt; padding-left: 4.9pt; font-size: 10pt; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">uidance on Travel and Expenses for Service Providers</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 15%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD>
    <TD STYLE="padding-left: 4.9pt; font-size: 10pt; width: 25%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the rare event that neither a receipt nor proof of payment is available (accidentally destroyed, lost,</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">etc.)
the specific reimbursement must be approved by the Service Provider&rsquo;s
direct supervisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Incomplete or incorrect expense reports will be returned
to the submitter for corrective action and may result in delay or non-reimbursement. Disregard for Company policy or altering of receipts
may result in breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">When required, the following table sets forth an acceptable
receipt for the indicated expense, provided that the receipt clearly displays the amount and date of the expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #DADADA">
    <TD STYLE="padding-right: 5pt; border: black 1pt solid; width: 26%; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expense Type</B></FONT></TD>
    <TD STYLE="padding-right: 5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 74%; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acceptable Receipt</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Air transportation</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travel itinerary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rail transportation</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boarding pass with total amount and date or Credit Card statement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental car</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental bill/receipt; or E-receipt</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parking</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Garage receipt or monthly bill</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5pt">Taxi/limo/ridesharing/car services</TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxi receipt, or invoice marked as paid</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tolls</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monthly Statement with reimbursable items highlighted</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hotel</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5pt">Detailed (itemized) hotel bill/folio; or itemized E-receipt. In addition, any hotel meal over $25.00 requires a receipt. Any hotel meal over $75.00 per attendee requires an itemized receipt.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meals</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5pt">Restaurant receipt for any meal over $25.00. Restaurant receipt and itemized bill inclusive of all charges and tips for any meal over $75.00 per attendee.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business entertainment</FONT></TD>
    <TD STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt (varies depending on type)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">All expense reports must be submitted to Company within
thirty (30) days of incurring the expense or after returning from a business trip. All travelers are responsible for promptly submitting
expense reports and complying with this policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">If you have any questions about the specifics of what is
reimbursable, please contact Trevena for a full copy of the Travel and Expense Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">3
  of 3</FONT></B></TD>
  <TD STYLE="width: 90%">This material is the property of Trevena and must not be disclosed
except as authorized in writing. This document is controlled electronically. If you are accessing it by means other than the Trevena
SharePoint Site, then you may not have the latest version and the information and integrity cannot be guaranteed.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2427743d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="text-align: center; font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Trevena Reports Third
Quarter 2024 Results and Provides Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CHESTERBROOK, Pa., November&nbsp;7,
2024 (GLOBE NEWSWIRE) &ndash;Trevena,&nbsp;Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization
of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter
ended September&nbsp;30, 2024 and provided an overview of its recent operational updates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Third Quarter 2024 and Recent Corporate
Updates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$2
                                            million Non-Dilutive Financing Tranche. </B>In July&nbsp;2024, the Company announced receipt
                                            of a non-dilutive, $2 million tranche in connection with an amendment (the &ldquo;Amendment&rdquo;)
                                            to its existing ex-US royalty financing with R-Bridge Healthcare Fund (&ldquo;R-Bridge&rdquo;).
                                            The Company is further eligible to receive up to an additional $8 million based on future
                                            milestones. As part of the Amendment, (i)&nbsp;certain OLINVYK Chinese IP that had been previously
                                            pledged to R-Bridge under the Royalty Financing was transferred to R-Bridge, (ii)&nbsp;warrants
                                            previously issued to R- Bridge as part of the Royalty Financing were amended to reduce the
                                            exercise price to a 15% premium to the then-current stock price and to extend the exercise
                                            period to five years from the effective date of the Amendment, (iii)&nbsp;the existing cap
                                            on the US royalty payable to R-Bridge was increased from $10 million to $12 million (with
                                            no minimum or fixed payments), and (iv)&nbsp;R- Bridge agreed to forgive $10.0 million of
                                            the amount that was outstanding to them prior to the Amendment. This $10.0 million forgiveness
                                            was determined to be a troubled debt restructuring and therefore no gain will be recognized
                                            by the Company for accounting purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
                                            Stock Split. </B>In August&nbsp;2024 the Company effected a 1-for-25 reverse stock of the
                                            Company&rsquo;s common stock (the &ldquo;Reverse Stock Split&rdquo;). As a result of the
                                            Reverse Stock Split, each 25 shares of the Company&rsquo;s issued and outstanding common
                                            stock were automatically combined into one validly issued, fully paid and non-assessable
                                            share of common stock. In addition, proportional adjustments were made to the number of shares
                                            of the Company&rsquo;s common stock issuable under the Company&rsquo;s equity incentive plans
                                            and all outstanding securities and other rights convertible or exercisable into shares of
                                            the Company&rsquo;s common stock, including all stock options and warrants outstanding immediately
                                            prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split did not have
                                            any effect on the stated par value of the Company&rsquo;s common stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
                                            Delisting and Subsequent Initiation of Trading on OTC Pink Sheets</B></FONT><B><FONT STYLE="font-size: 10pt"><I>.
                                            </I></FONT></B><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            October&nbsp;4, 2024, the Company announced that it had received notice that the Nasdaq Hearings
                                            Panel (the &ldquo;Panel&rdquo;) had determined to delist the Company&rsquo;s common stock
                                            from The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) due to the Company&rsquo;s failure
                                            to comply with the minimum stockholder&rsquo;s equity requirement under Nasdaq Listing Rule&nbsp;5550(b)(1)&nbsp;(the
                                            &ldquo;Equity Standard Rule&rdquo;). As previously disclosed, the Panel had provided the
                                            Company until October&nbsp;2, 2024, to regain compliance with the Equity Standard Rule. Trading
                                            in the Company&rsquo;s common stock was suspended on Nasdaq effective with the open of business
                                            on October&nbsp;8, 2024, and the Company&rsquo;s common stock began trading on the Pink Open
                                            Market operated by the OTC Markets Group,&nbsp;Inc. (commonly referred to as the &ldquo;pink
                                            sheets&rdquo;) on October&nbsp;8, 2024 under the trading symbol &ldquo;TRVN.&rdquo;</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
                                            Cost-Cutting Measures. </B>On October&nbsp;5, 2024, in connection with certain cost-cutting
                                            measures, the Board of Directors (&ldquo;the Board&rdquo;) approved the termination of employment,
                                            without cause, of three senior executives: Carrie Bourdow (President&nbsp;&amp; CEO), Mark
                                            Demitrack (SVP&nbsp;&amp; CMO), and Barry Shin (EVP&nbsp;&amp; COO/CFO). The terminations
                                            did not involve any disagreement concerning the Company&rsquo;s operations, policies or practices,
                                            and the Board thanked these executives for their service to the Company. Following the effectiveness
                                            of these terminations, Ms.&nbsp;Bourdow continues to serve as Chairman of the Board and Acting
                                            CEO; Mr.&nbsp;Demitrack continues to serve as Acting CMO; Mr.&nbsp;Shin continues to serve
                                            as Acting COO/CFO; and all entered into consulting agreements with the Company. Following
                                            these cost-cutting measures, the Company has four employees.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resignation
                                            of Certain Directors. </B>On November&nbsp;5, 2024, in connection with the ongoing cost-
                                            cutting measures, Mark Corrigan, M.D.; Marvin H. Johnson,&nbsp;Jr.; Jake R. Nunn; and Anne
                                            M. Phillips each informed the Company of his or her intent to resign from the Board and the
                                            committees thereof, effective as of November&nbsp;5, 2024. None of these resignations was
                                            related to any disagreement with the Company over any of its operations, policies or practices.
                                            Carrie Bourdow continues to serve as Chairman of the Board and Scott Braunstein, M.D. and
                                            Barbara Yanni continue to serve as directors of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.7pt"></TD><TD STYLE="width: 11.15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Continued
                                            Strategic Review. </B>The Company continues its review of strategic alternatives, including
                                            for OLINVYK, TRV045 and its other pipeline assets. There can be no assurance regarding the
                                            schedule for completion of the strategic review process, that this strategic review process
                                            will result in the Company pursuing any transaction or that any transaction, if pursued,
                                            will be completed. Potential strategic alternatives that may be explored or evaluated include,
                                            but are not limited to, a sale, license, divestiture or discontinuation of US commercial
                                            sales of OLINVYK; a sale, license or divestiture of our pipeline assets; or a sale, merger
                                            or wind down of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Financial Results and Other Updates
for Third Quarter 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">For the third quarter of 2024, the Company
reported a net loss attributable to common stockholders of $4.9 million, or $5.79 per share, compared to $7.9 million, or $14.20 per
share in the third quarter of 2023. Cash and cash equivalents were $13.5 million as of September&nbsp;30, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About Trevena</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Trevena,&nbsp;Inc. is a biopharmaceutical
company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one
approved product in the United States, OLINVYK<SUP>&reg;</SUP> (oliceridine) injection, indicated in adults for the management of acute
pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company&rsquo;s
novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for
diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use
disorder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">For more information,
please visit <U>www.Trevena.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black"><B>About
TRV045</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; color: Black">TRV045
is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for
acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes
of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">S1P
receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating
neurotransmission and membrane excitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">Trevena's discovery efforts
have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure
of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was
not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically
active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA. Subjects in both studies
referenced in this press release were enrolled outside of the United States, and the studies were not conducted under the Investigational
New Drug Application for TRV045.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black"><B>About OLINVYK<SUP>&reg;
</SUP>(oliceridine) injection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; color: Black">OLINVYK
is a new chemical entity approved by the FDA in August&nbsp;2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled
substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe
enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1
mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses
are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please
see Important Safety Information, including the BOXED WARNING, and full prescribing information at <U>www.OLINVYK.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt; color: Black"><B>IMPORTANT
SAFETY INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-left: 5pt"><B>WARNING:
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OLINVYK</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><B><U>Addiction,
Abuse, and Misuse</U></B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 10pt; padding-right: 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-left: 5pt"><B>Because
the use of OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and
death, assess each patient&rsquo;s risk prior to prescribing and reassess all patients regularly for the development of these behaviors
and conditions.</B></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Life-Threatening Respiratory Depression</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Serious, life-threatening, or fatal
respiratory depression may occur with use of OLINVYK, especially during initiation or following a dosage increase. To reduce the risk
of respiratory depression, proper dosing and titration of OLINVYK are essential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Risks From Concomitant Use With
Benzodiazepines Or Other CNS Depressants</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Concomitant use of opioids with benzodiazepines
or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma,
and death. Reserve concomitant prescribing of OLINVYK and benzodiazepines or other CNS depressants for use in patients for whom alternative
treatment options are inadequate.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Neonatal Opioid Withdrawal Syndrome</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>If opioid use is required for an
extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized
and treated. Ensure that management by neonatology experts will be available at delivery.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>INDICATIONS AND USAGE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">OLINVYK is an opioid agonist indicated
in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments
are inadequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Limitations of Use</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Because of the risks of addiction, abuse,
and misuse with opioids, which can occur at any dosage or duration, reserve OLINVYK for use in patients for whom alternative treatment
options [e.g., non-opioid analgesics or opioid combination products]:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 15.9pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
                                            not been tolerated or are not expected to be tolerated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 15.9pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
                                            not provided adequate analgesia or are not expected to provide adequate analgesia. The cumulative
                                            total daily dose should not exceed 27 mg.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CONTRAINDICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">OLINVYK is contraindicated in patients
with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 16.3pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            respiratory depression</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 16.3pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acute
                                            or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 16.3pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Known
                                            or suspected gastrointestinal obstruction, including paralytic ileus</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 16.3pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Known
                                            hypersensitivity to oliceridine (e.g. anaphylaxis)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2b2b2b"><FONT STYLE="font-size: 10pt"><B>WARNINGS AND PRECAUTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLINVYK
                                            contains oliceridine, a Schedule II controlled substance, that exposes users to the risks
                                            of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown,
                                            it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor
                                            all patients receiving opioids.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious,
                                            life-threatening respiratory depression has been reported with the use of opioids, even when
                                            used as recommended, especially in patients with chronic pulmonary disease, or in elderly,
                                            cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy,
                                            following a dose increase, or when used with other drugs that depress respiration. Proper
                                            dosing of OLINVYK is essential, especially when converting patients from another opioid product
                                            to avoid overdose. Management of respiratory depression may include close observation, supportive
                                            measures, and use of opioid antagonists, depending on the patient&rsquo;s clinical status.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioids
                                            can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-
                                            related hypoxemia with risk increasing in a dose-dependent fashion. In patients who present
                                            with CSA, consider decreasing the dose of opioid using best practices for opioid taper.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profound
                                            sedation, respiratory depression, coma, and death may result from the concomitant use of
                                            OLINVYK with benzodiazepines and/or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics,
                                            anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other
                                            opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs
                                            for use in patients for whom alternative treatment options are inadequate, prescribe the
                                            lowest effective dose, and minimize the duration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
                                            of OLINVYK for an extended period of time during pregnancy can result in withdrawal in the
                                            neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal
                                            syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period
                                            of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment
                                            will be available.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLINVYK
                                            was shown to have mild QTc interval prolongation in thorough QT studies where patients were
                                            dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied
                                            and may increase the risk for QTc interval prolongation. Therefore, the cumulative total
                                            daily dose of OLINVYK should not exceed 27 mg.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
                                            plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP)
                                            2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in
                                            patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6
                                            function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation
                                            of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely
                                            monitored for respiratory depression and sedation at frequent intervals. Concomitant use
                                            of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor
                                            can lower the expected concentration, which may decrease efficacy, and may require supplemental
                                            doses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioid-Induced
                                            Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain,
                                            or an increase in sensitivity to pain. This differs from tolerance where increasing doses
                                            are required to maintain the desired effect. Symptoms of OIH include, but may not be limited
                                            to, increased levels of pain upon dose increase, decreased levels of pain upon dose decrease,
                                            or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only
                                            if there is no evidence of disease progression, opioid tolerance, withdrawal, or addictive
                                            behavior. If OIH is suspected, carefully consider appropriately decreasing the dose of the
                                            current opioid analgesic or opioid rotation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cases
                                            of adrenal insufficiency have been reported with opioid use (usually greater than one month).
                                            Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue,
                                            weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement
                                            doses of corticosteroids and wean patient from the opioid.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLINVYK
                                            may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory
                                            patients. There is increased risk in patients whose ability to maintain blood pressure has
                                            already been compromised by a reduced blood volume or concurrent administration of certain
                                            CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients
                                            for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as
                                            it may cause vasodilation that can further reduce cardiac output and blood pressure.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avoid
                                            the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used
                                            with caution in patients who may be susceptible to the intracranial effects of CO2 retention,
                                            such as those with evidence of increased intracranial pressure or brain tumors, as a reduction
                                            in respiratory drive and the resultant CO2 retention can further increase intracranial pressure.
                                            Monitor such patients for signs of sedation and respiratory depression, particularly when
                                            initiating therapy.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases
                                            in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis,
                                            for worsening symptoms.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLINVYK
                                            may increase the frequency of seizures in patients with seizure disorders and may increase
                                            the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders
                                            for worsened seizure control.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Do
                                            not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually
                                            taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed
                                            agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g.,
                                            buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic
                                            effect and/or precipitate withdrawal symptoms.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLINVYK
                                            may impair the mental or physical abilities needed to perform potentially hazardous activities
                                            such as driving a car or operating machinery.</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
                                            self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient
                                            to individually titrate to an acceptable level of analgesia, PCA administration has resulted
                                            in adverse outcomes and episodes of respiratory depression. Health care providers and family
                                            members monitoring patients receiving PCA analgesia should be instructed in the need for
                                            appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects
                                            of opioid medications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>ADVERSE REACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Adverse reactions are described in greater
detail in the Prescribing Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The most common (incidence &ge;10%)
adverse reactions in Phase 3 controlled clinical trials were nausea,vomiting, dizziness, headache, constipation, pruritus, and hypoxia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>MEDICAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">For medical inquiries
or to report an adverse event, other safety-related information or product complaints for a company product, please contact the Trevena
Medical Inf<FONT STYLE="color: Black">ormation Contact Center at 1- 844-465-4686 or email MedInfo@Trevena.com.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">You
are encouraged to report suspected adverse events of prescription drugs to the FDA. Visit <U>www.fda.gov/medwatch or call 1-800-FDA-1088</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>PLEASE
see </B></FONT><B><FONT STYLE="font-size: 10pt; color: Black"><U>www.OLINVYK.com</U> for full prescribing information including BOXED
warning and important safety information</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; color: Black">Any
statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company&rsquo;s
strategy, future operations, clinical de</FONT><FONT STYLE="font-size: 10pt">velopment and trials of its therapeutic candidates, plans
for potential future product candidates and other statements containing the words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;suggest,&rdquo;
&ldquo;target,&rdquo; &ldquo;potential,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo;
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the expectations surrounding the continued advancement of the Company&rsquo;s product pipeline; the potential safety and efficacy
of the Company&rsquo;s product candidates and their regulatory and clinical development; the Company&rsquo;s intention to pursue strategic
alternatives for OLINVYK and the ability of any such strategic alternative to provide shareholder value; the expected financial and operational
impacts of the Company&rsquo;s decision to reduce commercial support for OLINVYK; the status, timing, costs, results and interpretation
of the Company&rsquo;s clinical trials or any future trials of any of the Company&rsquo;s investigational drug candidates; the uncertainties
inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company&rsquo;s
assessment of discussions with FDA; available funding; uncertainties related to continued listing on NASDAQ; uncertainties related to
the Company&rsquo;s intellectual property; uncertainties related to other matters that could affect the availability or commercial potential
of the Company&rsquo;s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the
Company&rsquo;s Annual Report on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q filed with the Securities and Exchange Commission
(SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in
this press release represent the Company&rsquo;s views only as of the date hereof. The Company anticipates that subsequent events and
developments may cause the Company&rsquo;s views to change. However, while the Company may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>For more information, please
contact: Company Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Bob Yoder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">SVP, Chief Business Officer&nbsp;&amp;
Head of Commercial Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Trevena,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">(610) 354-8840</FONT></P>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TREVENA,&nbsp;INC.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Condensed
Statements of Operations</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>(Unaudited, in thousands except share and per share data)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended
    Sept 30,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended Sept
    30,</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Product revenue</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">(21</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">1</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">13</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">28</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">License revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">304</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">179</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">615</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,179</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Total revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">180</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">628</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,207</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Operating expenses:</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Cost of goods sold</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">114</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">175</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">305</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">389</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Selling, general and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,572</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,323</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,799</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,866</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,260</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,958</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,160</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating
    expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,860</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,007</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,586</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,348</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,577</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,827</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,958</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,141</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">638</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">897</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,450</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,380</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,939</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,930</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,508</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(23,761</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Per
    share information:</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in">Net
    loss per share of common stock, basic and diluted</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">(5.79</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">(14.20</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">(20.54</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-align: right">(50.65</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 0.125in">Weighted average shares outstanding,
    basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">852,801</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">558,564</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">852,253</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">469,149</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>TREVENA,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Condensed Balance
Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Unaudited, in
thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30, 2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">13,462</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">32,975</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">282</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses and other current
    assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">991</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,230</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,205</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted cash, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">340</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">540</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">923</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,195</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Right-of-use lease assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,190</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">40,605</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and stockholders&rsquo; (deficit) equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">918</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,303</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other current
    liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,164</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,239</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Current portion of loans payable, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">902</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,086</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,554</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loans payable, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,972</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,809</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Leases, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,588</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,424</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">851</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,475</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,262</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">582,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">580,403</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(605,569</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(588,061</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Total stockholders&rsquo; (deficit)
    equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(23,309</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,657</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities and stockholders&rsquo; (deficit) equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">40,605</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2427743d1_ex10-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2427743d1_ex10-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 18# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BF29"-@
MX..", YR, $\9)X&>,FGD@=2!]?IG^0)^@JM*V5?YP.I'('*E6!)]#C!QU4G
M!!J97M963DU&+>RE*Z5^MFU9V3>I,I**OJ]).RW?*N9_@?#7[9/[8NC?LN:-
MHL=KI2^*_'WBI)AH?AN>Y-E8V^FV_F_:]>UFZ@AFNTLH)0EK#;VQ@GO+B556
M0HC%?Q^T[]M+]O7X@:I<>(_ ^L^*;[0;2Y>2;2?!GPUM-:\,60<),EE)=KX6
MUG44B,>_"'Q&;SR )VN4CDB:;K_^"L.E:K!^T)X>U*XBE?3M:^&FF6VC22G9
M"6TC6]46_@MV<$&2WFN+>>95P=MY;%PQ=,_L=^QM9^#H?V;/@XO@V*PBTFY\
M":'>7GV()#Y_B%]-M!XDFU QXEFU5M:%ZMZ]UNN%\N&.3 B0+_%.95>.O%_Q
MFXWX$CXA9YP#D7!6!PF(P&$X=F\#C\PKQKTL.L1BW"MAY8ZC-XB>)BH8FG?#
MQHJ2?)4IR_M?+:7A]X->!7 ''N+\,N'_ !)XF\2,UQ^%Q6+XHQ&*Q>5Y-A\%
M3K5GA*%+#QE/+:]=4Z>&H<D7?$1KRJ249P3_ #B^#_\ P52URSUFT\*_M$^"
MHM(B^W16>H>,/#$6IV,^D%MH%QXA\)ZQ;7MT;>WB(N+V;2[Z.[B022)ITB(R
M#]JM#U6QUS3[+6--O(=0TW5+2VO]/OX)8IK>\L[VVBN(+FWFA CE@>&0,DB%
MMV3R:_-O_@I%^S-X4\?_  C\4?&'1M!MK;XC_#C28]7N=8T]5BU#7?">E3/<
MZOHU^513?F&S$EWI,\[27%C<(Z1%8G=#T_\ P3'\=:CXQ_9@TG3=2F:YG\ ^
M)?$OA"";D[].BGM]:TZ,$HHVVUIK(LHP@VB*V0$Y!-?I'A_GG'W"7B%B_"CC
MW.O];,+6X>7$?"?%=?"4,-F&(PV78O#8/%X3'JA0HJOB:#Q-.<JLY8FK9253
M$.#IH_,_$?(O#KBOPYRWQ>\.L@K<'8JEQ5#A7C;A&.8U<QRW#X_'X/$8[*<=
ME,JZ]KALN=3#UZ,Z%3D?,H2IQ<HU$OTBII=0<$C([?Y].I]*7</4<\>M<!X[
M\8Z#X!\.>(O&/B?44TKP_P"&=,OM:UG4)'#+;:?86\L]V4A",TL[1[([:!?W
MEQ<RPP1!G-?T76K4L-1K8G$5:='#X:E4Q&(K59QITZ&'H4YU:]>I*325.C2I
MSJ5'JU%-I,_GBG3K5ZM##X:A5Q.)Q->EAL-AZ$'4K8C$XBI"CA\/1IQ3E.K7
MJU(TJ,$KSJSITHWG5IJ5_P 4>,_"_@_3YM9\7:_HOA?1X(S]HU'Q!JFGZ78Q
M!?,?+3WMS"CMMC9@D3/*% )0!LUY1X<_:4^ WC2^31_"_P 9/AUJ^IO.UO'I
MMEXGTAKV>9>#';V]S,AN'.05$)9W^ZO.5'\]7BGQ/\>?^"A?QO?1]!CGN-,M
MFN;KP]H37$UGX8\ ^$#>0QQZOK$Z(!-J<L<D9N-2: ZK>3S_ -FV#K#:@-ZY
M\;?^"9OB[X/_  OUKXG:-\2;#Q9>^"M.?Q'KNCQ^'KK0)TLM.E2;5Y_#VIIK
M6IW,DNGV GNX&DBAO+LQ%+8171B1OY)J?2#X\SV?$7$7A]X6U^(_#OAEXJ..
MS_&YMB,KKX^EEZKU<?CLIPWL^3%4J&&P>)JQ6&=7G@J5FY2J*'];Q^CMX<\/
M?V%P[XG>+M/A?Q'XHHX7^S^',!D-/.,)E6(S#V$,MR[/,PYG3PDL;B\7@<-0
MJU_9T\4Z]>I@W.CAI5#^BFR9G=,N"HRRKA0>,AF.PE3G/!4E2.5)R,[%?(W[
M%?B/Q1XH_9O^#>M^-+RZO/$%YX147%[>2F2YU"TMM6U6PT2\FE<%KAKS0;+3
M[DW!>3[0"MQYLHE\Q_K4RQ@D;AD'!P"<' /4#'0BOZER'-H9[D>2YU2HU,-3
MSC*,KS:GA*NM;"TLTP-#'4:-6;UG4]G7C*4I6E>5I)-6/Y7SC*JV19UG>18B
MI2JU\CSG-<FKU,.[X:=;*L?B,!5GATM(TISP_/%1;B^9N+:)**8)$/1OT/\
MA2AE)P#GMWQGTSTS[?4=0:]8\X=1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?)G[8W[6W@3]C3X%:[\</B!:ZGJNGZ=?6.B
M:'H.B1P#4?$WBG5K>\GT3P]%<WTL5CIBZHUE/#+J=],EI81![F4OL6&7\ HO
M^#D[45O=FI_LCZ=_9S289=/^-C3ZFT.0&>.WN_AG;V[.1\R1R3PJO'F/Z?T=
M?M"? ?P+^T9\)?&7P?\ B7I4>J>$?&6G2Z=?>1*\&I:<\MK/:Q:WI-SY4JV>
MKZ.UP;S39Q#(B2Q!9%P=P_@Y_:N_X)]?$?\ 8G^,/AGPS\=UU5O@9XF\:Z/9
M6/QR\&:<VMV&K>!QKFGKXBN+6Q:WO%TSQ]H7AF\-]-X5UJS$-_J"&/08]?L
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MN(GGT_3+PRVVH^'0BFWA_ >:_P#CS^R%\3-7^#_QA\-:SX=O?#%\EOKG@'Q
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M5U_QUXNM=<\+>!--\/:4GFW>J:G;31ZUK445K;3"UNM-T^:?RHM\D4O[;O\
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MD@96CD ,<BLI1P0"-K$@.6)VJJ%F8YPN!FI6D"IO8$#CC!)RS!1D $CDC)(
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MT>37;;1-T%YHVLV>HZ<=+\8:1+:PV^EZQ<VDMI+Y-TD,7QM^S?XJ\;_L2?\
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M&SMKGP]X'U#5O#WA;0]!)@>/2M>U*#Q)K6L1I-J4\\8N5+>H:_\ \$@OC?\
M 2TF^(G['_[5?CG3_'6@6\EZOAO7?[5\+6_B5;-+BX>S74/">JWUG?2RA4M[
M?0]>\*WVDZD[K%>7!A=D;]^O#>AZ3X9T;2_#VA646G:)H.FV6BZ/I]N,6UAI
M6DVT.G:?:6ZDG9!#:VD8C4$@Y=R=SDG;F_U;<[0-I)XX"L"3STP!G(P1U!!
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ML&DZ=XP3Q!XDACM=/AT.;PTMG'X<BU9?#(A31[FXM@?[):0K,[F9I K+]'T
M%%%% !1110 4Q^@^O^-%%-;KU7YH<?B7K_F-< 9P,<C^:?XG\S43 8/ Z'L*
M**YTW[:JKNWLD[=+WWMM?SM?S&F[0U?QKJ^S\RU3' QG'.>OX&BBMS.2ORWU
M][KZ,$Z'Z_T%/HHH*VVT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>trvn-20241105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiBubOdzZR++YkxtmB1bckaDygmk6TAViDCBZ1mUdAM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:trvn="http://trevenainc.com/20241105" elementFormDefault="qualified" targetNamespace="http://trevenainc.com/20241105">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://trevenainc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="trvn-20241105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="trvn-20241105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>trvn-20241105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>trvn-20241105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://trevenainc.com/role/Cover" xlink:href="trvn-20241105.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://trevenainc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45503956811328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TREVENA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001429560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1469215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">955 Chesterbrook Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chesterbrook<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">354-8840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRVN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MI3AG60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "E.&=9*?J"ZN\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "E.&=9F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( *4X9UD*004O.00  (00   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "E.&=9GZ ;\+$"
M  #B#   #0              @ %]#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( *4X9UF7BKL<P    !,"   +              "  5D/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( *4X9UFJQ"(6,P$  "("   /              "
M 4(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "E.&=9)!Z;HJT   #X
M 0  &@              @ &B$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "E.&=999!YDAD!  #/ P  $P              @ &'
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #1$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2427743d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trevenainc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2427743d1_8k.htm">tm2427743d1_8k.htm</File>
    <File>trvn-20241105.xsd</File>
    <File>trvn-20241105_lab.xml</File>
    <File>trvn-20241105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2427743d1_8k.htm": {
   "nsprefix": "trvn",
   "nsuri": "http://trevenainc.com/20241105",
   "dts": {
    "inline": {
     "local": [
      "tm2427743d1_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "trvn-20241105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "trvn-20241105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "trvn-20241105_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://trevenainc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427743d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427743d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://trevenainc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-115049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-115049-xbrl.zip
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M;#;=39X_FYIS.;5$S^9#ZL(6(J121LEG\N4(D(Q@6@P0_)SMV^-GX6QG"FH
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M=6F(A?BS0W4]^/G%9$2:!6$/0+--DSH"*OW@7]C>=?U>R9ZK!VC&C+N&1LV
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MW0Y]S60/MI<':Q4?!=37BL8 =%>(P D XBDA/^\;6;BC*S-'9/&FEZ0G!>D
MCY=6B+,"2Z3?-:J/24B_YR#3\3-P@9 \$R1QVAMA.7^.2V4:; SHAOJO]?7@
MG=%Q]!KNV4COP/-_DSX)P^X$)U/"LM<X[IDFE-L)_D!M'+X.UM?%./_FX.@/
MNR3?W+BUW6)O_!D_&Z09Z!SNL[T8U? M6%N>QB:"]9WO[AT?!ON'Q\<?=P\.
MCCZ\__7)YA/Z^^SC[K[]6^:4T<(TCM4TA[79WW8 4Z)BC"#:_&>;;'Q^:L<
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M2II"CP^&OO7/7#6N.&70THA! 5&+:L32*0KS).'YIV#//+HJN+MAR^%X@[E
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ML(-LHD!VLR.UK/VJ_'9-O-)>K31<H^@E)@^[2+ +S7W3AC:[34GT&'=L)+4
MU!&O!DZ/N96O67BU[^U@#)&![5_F!]E-TH3K%$B('H9 5!&7^MN:$*^N_.VO
M_-*D^1Z2%.]5AF]5/HBAF*+D\!@MLK]76<J*^52+00*\ZR5U3.XJ-DZPUQCC
M;EYBQJW&E'U@950\),ULN76-#1Y4HM,RIY) 0=I2U(H\7"%K3U+5I38-UVZ]
MHALS7U+6J$B9LC%A4D(3>W$UHY"K0"8R#J#V@U637*42^-Z9!>W$4I^F)D-B
MFPZ< 6A),VO**^O5:'7NPY<;/U--'N;T,.SO:L87YSEVK=]ZT9N+E:!^ =PR
MC"1?DE<12#6X( 6AJ-$!D>MD).47)B7%6'LEQ89^L58_R>-".S6T"OE?F3AN
M)C2W<,"]6#G@EM<!]V+E@/L/O;D+%1&6)L_7R@-^^QB1,*7W*]DB0;2D'![L
MY$W]-'2&=!]32D2 9U';\R20HX -.!B_+.5D K;F,^OP0L^!78'\&\=NJ!YW
M8&$F7:0CJIK8:YN@DE]HF39Y+(>;ZWOX4%+X*+Q*'(/X-M:T/$C#\@QP D3P
M_>.CPP_GHOZ<!4=G)QM'A_O!]LO-S2UBZ5R14:]3@R>J^F:KN%$=.BYSF=>]
M#@H+3^$++$8T"T(BX+P!T7/H[,'H:*FVXZJ9U!A\(#U[IN-9CI-9-\ZLU=8F
MS3>](\$RAUA$Q"[@OI.K+(5>="#S(F_L_]SEOIX=O?^P>_[I]+#;^;C[_C!X
M=W)\?/+GF;S^OSS4XXX2^GDEI"ROD/+S2DAYZ+(!BR,_\L$%T&V%B\HGP!O6
M0T!K(DS8.^1/;J(<_(E:(_9O\(A53:G$IHN.K3<->4ZC0YTS&)HLKVKLJ0&H
MT0^>_7*G:_Z$T.>:F\TH^<1B&=R)_1.<[L.O3YXUDFLJF,-;<72+#;>=?TVD
MD_K6$C+$D:I6)(,+Z!9UTSA^PGYU=9=ZZW-+_H$W*PRAQTL_2L+^4F[\1SC5
M!6]H#RAUZW8J*&XW2=(5<LSM1=N;%K61;\!K X!%\*\49EPAT_?>7'7&H*@5
MH*9-%<J_27J9J>GB#O9CAG4N(A'EVO'NGG%MB?%LBH6.DU$E55HQZ<= O@7?
MIG-T42XA,3O3"3J$_D#CR4<;.M8+]L?HZ=RS1>VY[>B#8N"=A5T10U&+^VI<
M^^I97]15N05L8^N&$>W$FU^QWZ7C/;L<S_MZR4C>CT/=KMS<@D3N5R]>  W1
M>:&S09:FGX.]M(PUZ,\1#% "#Y>Z#UN;/S(4? CT@H^[P=:KS5]>+N6.5TA]
M>WO!R8>S3\?GN^BB6%Z;P8]O*%C4)=T]/3TZ#([[P=[)I].#DS^7<K,_PDDN
MWCCP .(T:O_[*LN,)I1)RRQ*+U>XLM+]%ZZ:M6#9([J[B]!^[E%S:U_PX[_)
M*TWJ_C=W7P3BV?;+GX,]E<5Z%ARK1"\9&.ZPS259\7T='!Q6'BG,F2.=\/GS
MGQ=]=%ZUOF7TT=\NON7E=XUJ:0]_F M\6,5:M$1T>F$X7QT(=E4PQ>&7L1F8
M@E>ZZX=\W?^J%PLN&V!T.X#MO?UX>O)_#_?/ _CY\>1L]WCC[/#TCZ/]P[-O
M#5Y;"FA\%^3YF*68FO+Z1T*;N\5(-^M'VYYY6/F&FX_W A51L*PM^([UY;"?
M3Q),S51CYV5\FKI9AVF&*4*%#O("?XPX6X9SXUS/8UB1":GZ!M>YMX5/=!!^
M>Z.VI3B#[X*L[VS5_5-M)@-L,XQ!8(O"W>_$P6_8?;#0B-]=/T3_>T3@XQ&\
M#O[QXL7FQCAS:+ID()_K7[%0&.\M4QI$[29PN7A.^<,R2%0H BC3NFT_+>W/
MJ>JP7J<\6^EW Q0.29U7!P#O&54EE\I*5"0^'=KL7YM<Z.JJ1SH/,S. AS&@
M$P[AH0,OE[;L^/;U=<>W%]SN8:L6O8=JTGFF+G2,34R"-2H5RG\7,(Y?;NLB
MA8.-L KQ3\-,A5O;.VWEWL9IF<4S'.QI_[[*GZ\0X"X(L#V' *=>:QNXYHG&
MDG^8A5\XS)#R?UCK=B1IS4@F0A!P(J(45&%-(D4=,C!F\6G]I";3G>"0&^0$
M'T&+#*NF#UB^H% A=QGO66)CA2<N\B1E#.OZ#9*B,WROA,4?!6M(@\3/>$XS
M'LI4MC3N"BF7$BF?S2'EB=2,N (U65*6MI9MC(F2!JK2%*[BF#"H%1XL)1X\
MOXXX3;2*F1#%:32B%, \3T-#),*UUA*BY0I*<B?VJ^24%BJ&W]>)Q[TAR]>K
M%:AAM:8(WT'UJMBY3=\4KN^*S\*JQLC=J4>Y0+#6,*TJQ6D59RIYX5UCJ6F9
MN]*Y092&Y<165<=[:OE-MU.-F[LU4$E./%V=4W\@6SLF!"V:LU8C72A#%6U0
MA,&>]5F4]X/=:D.Y5R^S'$BQ44 %81W =@I:K%T:B=(39;-<7&'V_C0:NJ+K
M11J\.7K[YM-;1*@26.14S7"4_R-LL1^FDS<;G]YBM?8%Y"$MY,B7"O\^JAFE
M<5%-DM= [ OJ$%7,@K5GF]+A@MN]U4LF"TI1)7LYX'ZSRI&37Z5K"^>&18H2
MC"D!G)"[CMJN.50-QQVWB:IV9*! 71BL T.C/'B6V;*RDUMT6%JD;KY?T\TM
M1SGRBV.13"EF3_PY37,NY.,E'0JB<?&P>,;$QB7'5K5F8"2ON0^7"I)*O-3>
M40N!D\8^,JLKR"5T4\U5\\&/B29J1855K?Y.NW#=AR(I;5K4FE M.=^ZDT/K
MEY5#Z\=Q:.V]/=O_[?#@$U"SHP57$W#"V\GQT?Z_EM (?">L?[7"^N7#^JO.
ML6+//CMNLNLZYZL*.MQN[BMSQV],%Q?&;$,X3D_^=$&"5P=]TJ$RXFSW7\#R
MHK0$J78GL!ELU:DW<]I\%&0!<7X<MZ!%G<)"!J-_MU_V7[U8<!F6H]_?!V>G
M^[\^*2;;S[=?OGS^+-KZ?_K+UN;ZEIF,-K?Z?TU'3X+=X_-?GSSQW5C7QE+>
MX8C:'.J+.;;[*(>S]_9 -++@B!II#0VFU>VU'OT]+.C=T8=UX#+KFYN;6^N?
MSM;?'\#OVS>>%[5":S^QFT[TAF/YAB-_J!.M]\]\P,,\ #5R,M"9Y%:]P J5
MVYON,&\3)M<@L ],2._G_$ZU5 /_4"+T'O  M_N;JZMWEZ,[3KF@ZP.>V:>S
M![U@?)C/^Z]<D2*_:M'77<.%FC .#C_NGI[_?OCA_'73EG&;6-R;D/F:Z[!
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M5Z3T-J34!0)>04V)U(8U4GJNOIB-?>4<>GF-C.*WU$985>DF/9*J #GSX--
M4Y?AX]FPL-8DQ+$$(Z4 ^3A/S<I1WAPMEFOIJ=L/!"]^BND'NUUA@?9C27*
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M/NBW.OP,]\?3@,UDFAG<W529"#-2QC9WY"DGCS1K3GGEL20;3:#05)IM3JE
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M9]1&8WBFL;,1FN@C'</?&!^8)NLU^/># Y-G>H01:-S(EA.^I]QYE0(3T6N
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MP$=<<TU*-D@:TK-#0?Q!8/[2J&<"R(=_9O)H [F^'!B>#T][<@@G $933_Z
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MPSC 6LFB1,@+,+6/<E"H32L%G !)<R)?4.3PLB[))NF!= +#A]T 33NIBK?
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M2RS'Q'4Q-JZ(./6;OW5RY?XE"036(G&LJ?5@?'VU9 Z"'D.;>XQ\#_!GYDD
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M9%2D"S%1 M"OZ4($!^18.H-/0592 B@)-$HCG)D\0/DR$ROZ#AV,R:B;'W)
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MA\699"T:"^,&3"4].(5%O"?B43IH2F:BGSQ'-?Z/BH]<+&LRLP3P QSFJG\
MDLFEZ#B-JH4'4*5<A[@27U_[JF$#O5+82/&F\'3=(_V.(X&-9]B*UMAB>SL[
M6SN[+?C_O5V$3 Q1><&;45G]EUZJ!F!ETO YB>%YKCU_ +^, _:7GZ@+_D"<
M^DG(^RH*H*DD&SA?(!;58*(L!!H_8V98JG*+S\?M&OM#1C)F'[]]NKV]K?4<
M7NO[-^^ *F]Y#,X/5H5@\K.QM5>O;\$#6XWZWAY>K_?,VFO)#NIA;NWX)D D
M7IZ=M#LGZVN1$"PO"P]+84,?GQF6#.R$1T0\CTTNA;E'>5&1)84/+_[[Y'A]
M[9:'GFE>E4.D+2Q(4<(F_V2*^,,5)8 [#Q4$.R#2V3KS?>RH7E_K8#2:;NE\
M?GWW,Q!WO_8;AZKMC8 )4C0I]T9&S,S956J*=_TD!I*.,66I&H"5SXR*C'LJ
M-@&ZC:1A=A_KD=)Z^2*(W%+JI;G?F;FQ"!!&;?KPI%Y3AT%IQ=0[<(3!YIWJ
M_D:X/ETOHTJ^E$N!)6AQI"N?1(*5T39\+1V<?*QWM;Z&&TD#O0:65,FGOZ<7
M:_L@VY\>0V\ZV6[!F([86]?!/>)4-AO=%&&]#>D3\TU7N!*4R/C'>(_),/?S
M]37S!9W&^,^Q!]USQC\=\M'X1[C1B<]"-$ FW@G[_I\I2^FVQ0G 8B!3,?D2
M@\WQ+W!2T<1G&(0:_]">]J&*5TW^5"4N,]BHXEV"#N$8=C)AI<CXC3%6Z/2T
M%'&5%,D?*>:U= !@*+BGQ]E=4SQ WF!HJR-L=#DQ9W &?^A!-U>"<@9M.Z;!
MA(W]_58-_X5#_55X4?7DJ/9=A@<=JM2"[D%1_:SF>KCN2"4,[H!4ETO2A"\
M\8;3*/6<;NF!R8B%E7B/LF;.#[G^?L5LL$P8XDA'0\0&HV3P8-NH&5$]A8U3
M1@ED $3M@8]'0Z)3?M+JC:*B>E( 6.%WOVN,Z>"G$LO&^Z9X'3_,"8B4]P^F
MOI781)6B^RQ(PB@13,L>3(;F)@HJH9:6P.O:4=/%0'%D?2CI\\6!A-D5D]$
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MV1_$^)CK3.<D@X3957]Y6KIOA0!] Z^?B;4\GF&)#.RC"\3G^;_>[(XC<X9
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M>:\1><]C5^L+=)]$<J/4ODBGGF'+AA>)Z,,T!)7(?#VZNN"^\R_SKGM/_OD
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M83I:S!-T8Y7AH, /L;]H-:A@I[KPXX%%,HO#W-+%$B]#'#H9C\A4Q. '7:-
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MZR&#L$PQ#\=U8_$/8+]&&'S6!/VGX-BP1TQ!.?BF$6BXF9HZ_@%02P,$%
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MH+P6V^^7US==RT]RL]XD_UKAE,@M_P502P,$%     @ I3AG6>@JWFE9!P
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MJ@KPATH@[S>8O,N\(6'^.R/*4,77$-(G8B#LMYBP/0Z1>#\I(C1S?"# 3]5
MXK^A7GAX/"(A'\THYRZ-(P*TEY?I@=A_Q\3N]_D*P-\NW/G=GEK@[/>* /'_
M\5KPG[A%BL #54PF]I2N .Q/Q$#JYYC4/0Y1>=^*!$I[)P7G/_BPC^PAH1XP
M'1->]&A@M^DP[A(Y%#E*SEEI$Q7[OY0H,/0],10Y2AI:8;%FX/U,J8/.!$<5
MOQJ*'"4!K3)9,_-;89A9N_O^G[-T_./&Z2'K4Q64,4K2Z3.%PG9[IT$8]S@C
MQ/=8"66,DFN&S*%P[EL_BO"A2.CJ(UV'0)](H:11<LR@/134#XJE1*U'+*X>
M-$ZU4-@HF678( KM)[(:)M85F[#B@6 U=&\1*'N4M!)D%R4$0Q%+-9=[MXO[
M,K/'X[HOD^"07E$0&@Z4?/,%UE&"<ITD%I?>_+EC@G9"H2B5@Y\1X04@8/.5
M8.^^#'L7CATE#ZVT^4JP]UZ&O0?'CI*+5MK$Q-ZW'^_5DUQZGD![Q5#D*+EH
MA45,X/F9YEX]*+E@Q;RH*NHG):#H$5/4L%G4';XXR4/V]JT2RALQ72TWA\GY
M06I#^']L7G4E6:Z',D=,7$-&Z[[!6,3=W;3P324ZDD#YHN2JI7;J1NHBK"CQ
M[[Z'"BA0E 2TS$S-/.^D>_8QDR)X/_94!>6*DDGZ3-4]\+JIQ-I[Z.]]#9[!
MAC*L'MNH&>,WQ8SM05^F:28V]V@\3\4\4BA>E/0O:*]FU"/)6<P,$]-/]@I1
M,<++.9?IH)!1DCV_L9H)/RCJ(DWM97<^C\NM-5#WDXEOY WIH<11<KUJH[CD
MAUIG5+V4?TDI:!10TCZHZ;K'&1IG=MA;=[KC)[=BQC/*G*B@K%%2/I^IFME^
MED^*N/5ZHW4ZEMR_/*14""6,DN %K-4,^: ?Y7B/)%"P*)E=J1VD,>%V%<^(
MF%+_[(5R)10P2J87,H<V]DY!8^_TA6,O2L;G,X7$MI@;;H^H^S%G4^)?218L
M %YG@TD\8+7N]7OYDA^WDENE>3\&]D,Y=H\4"AQGB63(7MVHLX09FA1=&C!!
M1&Q3JMVZ-D]V7ET*&@"<-91 TRBW][]1SC\*N10C2K04-"DN]4-W^+U%H%%
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M-S<T,V0Q7V5X,3 M,2YH=&U02P$"% ,4    " "E.&=9]':L\9TR  !GS0$
M%@              @ 'A2P  =&TR-#(W-S0S9#%?97@Y.2TQ+FAT;5!+ 0(4
M Q0    ( *4X9UE*(L6)+ ,  .D+   1              "  ;)^  !T<G9N
M+3(P,C0Q,3 U+GAS9%!+ 0(4 Q0    ( *4X9UG4I4R;_@H  ("&   5
M          "  0V"  !T<G9N+3(P,C0Q,3 U7VQA8BYX;6Q02P$"% ,4
M" "E.&=9Z"K>:5D'  #95P  %0              @ $^C0  =')V;BTR,#(T
B,3$P-5]P<F4N>&UL4$L%!@     &  8 C0$  ,J4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2427743d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="trvn-20241105.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001429560</identifier>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-05" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-05" id="Fact000004">0001429560</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-05" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-05" id="Fact000010">2024-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-05" id="Fact000011">TREVENA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-05" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-05" id="Fact000013">001-36193</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-05" id="Fact000014">26-1469215</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-05" id="Fact000015">955 Chesterbrook Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-05" id="Fact000016">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-05" id="Fact000017">Chesterbrook</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-05" id="Fact000018">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-05" id="Fact000019">19087</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-05" id="Fact000020">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-05" id="Fact000021">354-8840</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-05" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-05" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-05" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-05" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-05" id="Fact000026">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-05" id="Fact000027">TRVN</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-05" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
